SOURCE: iSatori

iSatori

June 30, 2014 10:56 ET

First Ever Clinical Study on Bio-Active Peptides, With iSatori's Sports Supplement Category-Creating Bio-Gro™, Presented at Annual ISSN Scientific Symposium

Double-Blind, Placebo-Controlled Clinical Trial Confirms Bio-Gro Bioactive Peptides Improves Muscular Performance in Men

GOLDEN, CO--(Marketwired - Jun 30, 2014) - iSatori, Inc. (OTCQB: IFIT), an emerging leader in the development and marketing of scientifically engineered nutritional supplements for healthier lifestyles, today released the results of the clinical study on bio-active peptides (Bio-Gro™) it funded, which was recently performed at the University of Central Florida Institute of Exercise Physiology and Wellness and presented at the Annual ISSN Scientific Conference in Clearwater, Florida.

Stephen Adelé, founder and Chief Executive Officer of iSatori, commented, "I'm proud of iSatori for being the first sports nutrition company to ever fund a study on bio-active peptides [Bio-Gro™] and their impact on muscular performance. This opens the door to enormous possibilities for us as a company where, once you've paved the way and have firmly established a new product category in sports nutrition, the market rewards you handsomely. These are definitely exciting times at iSatori, and the future looks bright for Bio-Gro™ and its users."

The study on bio-active peptides (Bio-Gro™) was headed up by Drs. Jay Hoffman and Jeffrey Stout, whose faculty presented the abstract and poster at the annual International Society of Sports Nutrition (www.JISSN.com) scientific symposium on June 21, 2014. The scientific abstract has also been posted at http://www.bio-gro.org/study.html.

Director of Science and Education for iSatori, David Sandler, added, "This was a very complex study designed to isolate the influence of Bio-Gro™ bio-active peptides on performance measures, ruling out all potential confounding factors commonly found in standard training studies. Our purpose was to understand the minimum amount of Bio-Gro needed to elicit a positive training and performance effect. The results confirm we have a supplement that has remarkable possibilities to enhance training performance and reduce recovery time. We intend to fund additional studies on Bio-Gro that are longer term and measure overall strength and muscle-growth possibilities."

The authors of the study concluded, "The current results suggest that supplementing with BAP's [Bio-Gro™] during the early phase of a training program may aid in reducing the recovery time between bouts of strenuous exercise. By encouraging faster recovery, BAP supplementation may promote earlier adaptations to training (i.e., increased strength and training volume) as compared to training without supplementation."

To learn more about iSatori and Bio-Gro™, visit www.iSatori.com/biogro; or for more in-depth science on Bio-Gro™, visit www.bio-gro.org. Bio-Gro is available at leading retailers nationwide, including GNC, Vitamin World, VitaminShoppe, and online retailers like bodybuilding.com, Tigerfitness.com, CampusProtein.com, and hundreds of others. Retailers interested in carrying Bio-Gro™ can contact Europa Sports at 1-800-447-4795 or visit http://www.EuropaSports.com.

Watch the Bio-Gro commercial here: https://www.youtube.com/watch?v=S73x1llie-A

Sign up for iSatori email alerts here: http://www.isatori.com/Email-Signup-C2041.aspx

About iSatori, Inc.

iSatori is a consumer products firm that develops and sells nutritional products through online marketing, Fortune 500 retailers, and thousands of retail stores around the world. The Company is headquartered in Golden, Colorado, and its common stock trades on the OTCQB under the symbol "IFIT." More information about the Company is available at http://www.isatori.com.

Forward-Looking Statements

Statements made in this news release relating to the Company's future sales, expenses, revenue, product developments, and all other statements except statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We have used the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," "potential," and similar terms and phrases to identify forward-looking statements in this press release. These statements are based on assumptions and estimates that management believes are reasonable based on currently available information; however, management's assumptions and the Company's future performance are both subject to a wide range of business risks and uncertainties, and there is no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the timing and extent of changes in demand for the Company's products, the availability and price of ingredients necessary to manufacture such products, and the outcome of any current or future litigation regarding such products or similar products of competitors. Please see our Risk Factor disclosures included in our Registration Statement on Form S-1, as amended, initially filed with the Securities and Exchange Commission on April 30, 2013, and in subsequent filings with the Securities and Exchange Commission. All future written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. The forward-looking statements herein speak as of the date of this press release. We undertake no obligation to update any information contained herein or to publicly release the results of any revisions to any forward-looking statements that may be made to reflect events or circumstances that occur, or that we become aware of, after the date of this press release.

Multimedia